Cash, cash equivalents and marketable securities as of June 30, 2024, were $595.4 million as compared to $341.6 million as of December 31, 2023. The increase reflects the receipt in April 2024 of the upfront payment from the Takeda Worldwide License and Collaboration Agreement for rusfertide entered in Q1 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics announces publication of clinical data on JNJ-2113
- Protagonist Therapeutics appoints Newman Yeilding as chief scientific advisor
- Protagonist Therapeutics price target raised to $51 from $41 at BTIG
- Protagonist Therapeutics to replace Encore Wire in S&P 600 at open on 7/3
- 3 Best Stocks to Buy Now, 6/17/2024, According to Top Analysts